Assessment of leptin and resistin levels in non-obese multiple myeloma patients and their relation with Ig level and disease stage

Abstract

Introduction: Multiple myeloma (MM) accounts for approximately 0.8% of all cancer diagnoses and 0.9% of cancer deaths. Leptin receptors were expressed on CD34+ cells. Resistin receptors were expressed on inflammatory cells and pro-inflammatory cytokines increase the expression of resistin on monocytes. Aim of work: To assess the level of leptin and resistin in non-obese multiple myeloma patients and to study their relation with Ig level and disease stage. Subjects & methods: 32 subjects were included; 16 patients diagnosed with MM and 16 healthy individuals served as control. All were subjected to history taking, clinical examination, routine laboratory investigations and leptin & resistin blood level. Laboratory investigations were done for diagnosis and staging for MM patients. Results: Leptin was significantly higher in MM patients compared with the control group, unlike resistin which showed no significant difference between the two groups. A significant positive relation was found between IgG level & leptin. Similarly, a significant difference in leptin level has been observed between stage I & stage II (higher in II). Conclusions: Leptin may play a role in the pathogenesis of MM and its level may be changed in different stages.

Keywords

• Leptin
• Resistin
• Multiple myeloma